Anti-Toxoplasma activity of Sorghum bicolor-derived lipophilic fractions
OBJECTIVE: Toxoplasma gondii, an intracellular zoonotic parasite, infects approximately a third of the world population. Current drugs for treatment of T. gondii infection have been challenged with ineffectiveness and adverse side effects. This necessitates development of new anti-Toxoplasma drugs....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814109/ https://www.ncbi.nlm.nih.gov/pubmed/31651353 http://dx.doi.org/10.1186/s13104-019-4732-z |
_version_ | 1783462960926031872 |
---|---|
author | Abugri, Daniel A. Jaynes, Jesse M. Witola, William H. |
author_facet | Abugri, Daniel A. Jaynes, Jesse M. Witola, William H. |
author_sort | Abugri, Daniel A. |
collection | PubMed |
description | OBJECTIVE: Toxoplasma gondii, an intracellular zoonotic parasite, infects approximately a third of the world population. Current drugs for treatment of T. gondii infection have been challenged with ineffectiveness and adverse side effects. This necessitates development of new anti-Toxoplasma drugs. Sorghum bicolor [Moench] leaf extract has been used in African traditional medicine for the management of anemia and treatment of infectious diseases. We tested the in vitro anti-Toxoplasma inhibitory activity of S. bicolor’s oil-like crude extracts and fractions against T. gondii and determined their cytotoxic effects on human host cells. RESULTS: Significant inhibitory activities against the growth of T. gondii tachyzoites were observed for the crude extract (IC(50) = 3.65 µg/mL), the hexane-methanol fraction (IC(50) = 2.74 µg/mL), and the hexane fraction (IC50 = 3.55 µg/mL) after 48 h of culture. The minimum cytotoxicity concentrations against HFF were 34.41, 16.92 and 7.23 µg/mL for crude extract, hexane-methanol and hexane fractions, respectively. The crude extract and fractions showed high antiparasitic effects with low cytotoxic effects. Further studies to determine synergistic activities and modes of action would provide impetus for the development of new toxoplasmosis drugs or nutraceuticals. |
format | Online Article Text |
id | pubmed-6814109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68141092019-10-31 Anti-Toxoplasma activity of Sorghum bicolor-derived lipophilic fractions Abugri, Daniel A. Jaynes, Jesse M. Witola, William H. BMC Res Notes Research Note OBJECTIVE: Toxoplasma gondii, an intracellular zoonotic parasite, infects approximately a third of the world population. Current drugs for treatment of T. gondii infection have been challenged with ineffectiveness and adverse side effects. This necessitates development of new anti-Toxoplasma drugs. Sorghum bicolor [Moench] leaf extract has been used in African traditional medicine for the management of anemia and treatment of infectious diseases. We tested the in vitro anti-Toxoplasma inhibitory activity of S. bicolor’s oil-like crude extracts and fractions against T. gondii and determined their cytotoxic effects on human host cells. RESULTS: Significant inhibitory activities against the growth of T. gondii tachyzoites were observed for the crude extract (IC(50) = 3.65 µg/mL), the hexane-methanol fraction (IC(50) = 2.74 µg/mL), and the hexane fraction (IC50 = 3.55 µg/mL) after 48 h of culture. The minimum cytotoxicity concentrations against HFF were 34.41, 16.92 and 7.23 µg/mL for crude extract, hexane-methanol and hexane fractions, respectively. The crude extract and fractions showed high antiparasitic effects with low cytotoxic effects. Further studies to determine synergistic activities and modes of action would provide impetus for the development of new toxoplasmosis drugs or nutraceuticals. BioMed Central 2019-10-24 /pmc/articles/PMC6814109/ /pubmed/31651353 http://dx.doi.org/10.1186/s13104-019-4732-z Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Note Abugri, Daniel A. Jaynes, Jesse M. Witola, William H. Anti-Toxoplasma activity of Sorghum bicolor-derived lipophilic fractions |
title | Anti-Toxoplasma activity of Sorghum bicolor-derived lipophilic fractions |
title_full | Anti-Toxoplasma activity of Sorghum bicolor-derived lipophilic fractions |
title_fullStr | Anti-Toxoplasma activity of Sorghum bicolor-derived lipophilic fractions |
title_full_unstemmed | Anti-Toxoplasma activity of Sorghum bicolor-derived lipophilic fractions |
title_short | Anti-Toxoplasma activity of Sorghum bicolor-derived lipophilic fractions |
title_sort | anti-toxoplasma activity of sorghum bicolor-derived lipophilic fractions |
topic | Research Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814109/ https://www.ncbi.nlm.nih.gov/pubmed/31651353 http://dx.doi.org/10.1186/s13104-019-4732-z |
work_keys_str_mv | AT abugridaniela antitoxoplasmaactivityofsorghumbicolorderivedlipophilicfractions AT jaynesjessem antitoxoplasmaactivityofsorghumbicolorderivedlipophilicfractions AT witolawilliamh antitoxoplasmaactivityofsorghumbicolorderivedlipophilicfractions |